Minnesota judge narrows charges in class action suit against Mylan, pharmacy benefit managers over EpiPen price hikes
Second time’s the charm for Viatris and a suite of pharmacy benefit managers in a proposed class-action lawsuit alleging collusion over price hikes for the company’s EpiPen.
After trying — and succeeding, in part — to get claims against them dismissed back in 2021, the defendants celebrated a win on Tuesday when a Minnesota federal judge dismissed a large chunk of the claims due to a lack of evidence.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.